Hikma Pharmaceuticals maintains 2026 outlook
The drugmaker expects to absorb higher costs from the Iran war while maintaining revenue targets. Shares rose 6% as robust demand offsets supply chain risks.
HIKMA PHARMACEUTICALS PLC has reaffirmed its 2026 financial outlook, signaling confidence in its ability to navigate geopolitical volatility and rising operational expenses. The United Kingdom-based drugmaker announced on Thursday that it expects to absorb increased shipping, energy, and insurance costs resulting from the ongoing conflict in Iran, bolstered by resilient demand for its products.
The company’s share price surged nearly 6% following the update, providing a much-needed boost for Chief Executive Said Darwazah. Darwazah recently pivoted from his role as executive chairman to focus exclusively on addressing the structural challenges that have impacted the firm's valuation over the past year. Analysts at Peel Hunt described the announcement as a positive step toward stabilizing investor sentiment.
